Finance Watch: Frontier Raises $80m For Differentiated KRAS G12C Program

Frontier Medicines Corp. has raised $235.5m in venture capital to date, including an $80m series C round unveiled on 22 February, although this latest financing is slightly smaller than its $88.5m series B round announced in July 2021. The company has progressed its pipeline since then – taking lead drug candidate FMC-376 into the clinic – and plans to accomplish a lot with its new funding, advancing multiple programs into clinical trials.

Boston- and South San Francisco-based Frontier raised $67m in series A funding in 2019 and its series B round two years later, saying in 2021 that it would further develop its precision medicine platform and advance its pipeline of targeted therapeutics, which included an inhibitor of activated and inactivated (ON and OFF) KRAS G12C